Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How

Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervent...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Olubanke, Ustianowski, Andrew, Fox, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125131/
https://www.ncbi.nlm.nih.gov/pubmed/27677264
http://dx.doi.org/10.1007/s40121-016-0128-8
_version_ 1782469937007165440
author Davies, Olubanke
Ustianowski, Andrew
Fox, Julie
author_facet Davies, Olubanke
Ustianowski, Andrew
Fox, Julie
author_sort Davies, Olubanke
collection PubMed
description Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervention, populations that may benefit, current guidelines and programmes, and the cost-effectiveness modelling of this strategy.
format Online
Article
Text
id pubmed-5125131
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51251312016-12-13 Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How Davies, Olubanke Ustianowski, Andrew Fox, Julie Infect Dis Ther Review Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervention, populations that may benefit, current guidelines and programmes, and the cost-effectiveness modelling of this strategy. Springer Healthcare 2016-09-27 2016-12 /pmc/articles/PMC5125131/ /pubmed/27677264 http://dx.doi.org/10.1007/s40121-016-0128-8 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Davies, Olubanke
Ustianowski, Andrew
Fox, Julie
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title_full Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title_fullStr Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title_full_unstemmed Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title_short Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
title_sort pre-exposure prophylaxis for hiv prevention: why, what, who and how
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125131/
https://www.ncbi.nlm.nih.gov/pubmed/27677264
http://dx.doi.org/10.1007/s40121-016-0128-8
work_keys_str_mv AT daviesolubanke preexposureprophylaxisforhivpreventionwhywhatwhoandhow
AT ustianowskiandrew preexposureprophylaxisforhivpreventionwhywhatwhoandhow
AT foxjulie preexposureprophylaxisforhivpreventionwhywhatwhoandhow

Ejemplares similares